Interleukin – 6 ELISA ( IL-6 ELISA)
IL-6 ELISA kit with 2 level controls
In vitro diagnostic ( IVD) ELISA kit suitable for human diagnosis
IL- 6 has been identified as an important biomarker for COVID-19 disease monitoring.
Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm. (1)
COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation.(1)
IL-6 is an effective marker that might be able to predict upcoming respiratory failure with high accuracy and help physicians correctly allocate patients at an early stage. (2)
Thus, in patients with COVID-19, IL-6 levels are significantly elevated and associated with adverse clinical outcomes. (3)
Contact us for more info
Interleukin – 6 ELISA ( IL-6 ELISA) features
IL-6 ELISA kit is based on sandwich EASIA principle ( Enzyme Amplified Sensitivity ImmunoAssay) for enhanced sensitivity.
Sample volume required 100 microl only
Wide linearity range of 23.3- 2560 pg/ml
2 levels of controls provided
Excellent analytical sensitivity of 2 pg/ml
CE marked IL-6 ELISA kit
Hands on time of 2.5 hours at RT with shaking at 700 rpm
IVD ( In vitro Diagnostic) kit and not RUO ( Research Use Only ) kit thus suitable for human diagnosis
IL-6 or Interleukin -6 has been identified as an important cytokine as it is involved in varied functions like immune response cascade, differentiation and growth. It exhibits both proinflammatory and anti-inflammatory functions. The most important functions of IL-6 include differentiation of B-cells for antibody production and production of acute- phase reactants like CRP, SAA, and reduction of albumin by hepatocytes.
The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome like disease. Dennis Macgongale, Kassem Sherrif
Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. Tobias Herald MD
Interleukin-6 in COVID-19 : A systematic review and meta- analysis. Erid A. Coomes